This article is more than 5 years old. Information may no longer be current.
First patient treated in 3-month DAPT trial
Click Here to Manage Email Alerts
Abbott announced that the first patient has been treated in a clinical trial evaluating 3-month dual antiplatelet therapy after receiving a drug-eluting coronary stent.
The study will compare DAPT for 3 months to the current standard of 12 months after everolimus-eluting stent (Xience, Abbott) implantation.
“Limiting the duration of blood thinning medicine from 12 months to 3 months is particularly important for people at higher risk of bleeding due to factors such as older age, anemia and renal disease,” Roxana Mehran, MD, professor of medicine and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai, and Cardiology Today's Intervention associate medical editor, said in the release. “The results of this study will help determine if doctors can safely reduce the amount of time that high bleeding-risk patients must take blood thinning medication after receiving a Xience stent to unblock coronary arteries.”
The trial, XIENCE Short DAPT, is a single-arm nonrandomized study that will assess for rates of MI or death in high-bleeding risk participants.
The study aims to enroll about 2,000 participants at 100 sites in the U.S. and Asia.